GlucoCEST MRI in Oncology
Head and Neck Squamous Cell Carcinoma, Lymphoma, Glioma
About this trial
This is an interventional basic science trial for Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria:
Healthy Volunteers:
- No previous history of cancer
- No known renal impairment or an eGFR within a standard reference value if there is a history of renal disease.
- Aged 18 or over with capacity to consent.
Patient groups:
- Confirmed diagnosis of selected cancer types (head and neck, lymphoma and glioma)
- No known renal impairment or an eGFR within a standard reference value if there is a history of renal disease
- Aged 18 or over with capacity to consent.
Exclusion Criteria:
For both groups:
- Confirmed diagnosis of selected cancer types (head and neck, lymphoma and glioma)
- Pregnancy
- Contradiction to MRI magnetic field (pacemaker, metallic implant, severe claustrophobia, etc)
- Allergy to MR contrast agent (Gadolinium)
- Adult with Impaired capacity
- Deranged renal function with eGFR
Sites / Locations
- University College London Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
GT1
GT2
GT3
Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.